Ovulation-stimulation drugs and cancer risks: a long-term follow-up of a British cohort
Open Access
- 12 May 2009
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 100 (11), 1824-1831
- https://doi.org/10.1038/sj.bjc.6605086
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Cancer Risk After Exposure to Treatments for Ovulation InductionAmerican Journal of Epidemiology, 2008
- Cervical carcinoma and reproductive factors: Collaborative reanalysis of individual data on 16,563 women with cervical carcinoma and 33,542 women without cervical carcinoma from 25 epidemiological studiesInternational Journal of Cancer, 2006
- Tamoxifen Treatment for Breast Cancer and Risk of Endometrial Cancer: A Case-Control StudyJNCI Journal of the National Cancer Institute, 2005
- Ovarian Cancer Risk After the Use of Ovulation-Stimulating DrugsObstetrics & Gynecology, 2004
- Risk of cutaneous melanoma in a cohort of infertile womenMelanoma Research, 1995
- Proportional hazards tests and diagnostics based on weighted residualsBiometrika, 1994
- Ovulation induction with human menopausal gonadotropins – a changing sceneGynecological Endocrinology, 1991
- Deprivation: explaining differences in mortality between Scotland and England and Wales.BMJ, 1989
- Follicular stimulation for high tech pregnancies: are we playing it safe?BMJ, 1989
- Partial residuals for the proportional hazards regression modelBiometrika, 1982